Beam Therapeutics (BEAM) Accounts Payables (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Accounts Payables data on file, last reported at $12.3 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 59.58% year-over-year to $12.3 million in Q1 2026; TTM through Mar 2026 was $12.3 million, a 59.58% increase from a year earlier, with the FY2025 full-year figure at $10.2 million, up 164.3% from the prior year.
• Accounts Payables for Q1 2026 stood at $12.3 million, up from $10.2 million in the prior quarter.
• Over the last five years, Accounts Payables for BEAM reached as high as $14.1 million in Q1 2023 and fell as low as $1.6 million in Q4 2023.
• Historically, Accounts Payables has averaged $7.1 million across 5 years, with a median of $7.0 million in 2022.
• Across the five-year window, Accounts Payables sank 82.09% in 2023 and surged 175.95% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $9.0 million in 2022, then sank by 82.09% to $1.6 million in 2023, then surged by 139.39% to $3.9 million in 2024, then soared by 164.3% to $10.2 million in 2025, then gained by 20.09% to $12.3 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $12.3 million in Q1 2026, $10.2 million in Q4 2025, and $9.5 million in Q3 2025.